{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T18:07:02Z","timestamp":1771870022665,"version":"3.50.1"},"reference-count":92,"publisher":"The Endocrine Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,8,1]]},"DOI":"10.1210\/er.2001-6002","type":"journal-article","created":{"date-parts":[[2002,8,30]],"date-time":"2002-08-30T17:22:48Z","timestamp":1030728168000},"page":"540-551","source":"Crossref","is-referenced-by-count":101,"title":["VI. Meta-Analysis of Calcitonin for the Treatment of Postmenopausal Osteoporosis"],"prefix":"10.1210","volume":"23","author":[{"given":"Ann","family":"Cranney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Tugwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Zytaruk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beverley","family":"Shea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Wells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Waldegger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon","family":"Guyatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The Osteoporosis Methodology Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The Osteoporosis Research Advisory Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2016,11,7]]},"reference":[{"issue":"Suppl 5B","key":"2019041123400437400_R1","doi-asserted-by":"crossref","first-page":"19S","DOI":"10.1016\/0002-9343(91)90242-P","article-title":"Effect of calcitonin on bone mass and fracture rates","volume":"91","author":"Reginster","year":"1991","journal-title":"Am J Med"},{"issue":"Suppl 5A","key":"2019041123400437400_R2","doi-asserted-by":"crossref","first-page":"44S","DOI":"10.1016\/0002-9343(93)90382-Y","article-title":"Calcitonin for prevention and treatment of osteoporosis","volume":"93","author":"Reginster","year":"1993","journal-title":"Am J Med"},{"key":"2019041123400437400_R3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF00310194","article-title":"Effects of calcitonin on bone quality and osteoblastic function.","volume":"52","author":"Wallach","year":"1993","journal-title":"Calcif Tissue Int"},{"issue":"Suppl 2","key":"2019041123400437400_R4","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1007\/BF02561368","article-title":"Future horizons for calcitonin: a US perspective","volume":"49","author":"Carstens","year":"1991","journal-title":"Calcif Tissue Int"},{"key":"2019041123400437400_R5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0889-857X(05)70193-9","article-title":"Calcitonin.","volume":"27","author":"Silverman","year":"2001","journal-title":"Rheum Dis Clin North Am"},{"key":"2019041123400437400_R6","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/bmj.305.6862.1124","article-title":"Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture.","volume":"305","author":"Kanis","year":"1992","journal-title":"BMJ"},{"key":"2019041123400437400_R7","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2165\/00002512-199608050-00006","article-title":"Intranasal salcatonin: a review of its pharmacological properties and role in the management of postmenopausal osteoporosis.","volume":"8","author":"Plosker","year":"1996","journal-title":"Drugs Aging"},{"key":"2019041123400437400_R8","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1055\/s-2007-1002156","article-title":"Neutralizing antibodies against calcitonin.","volume":"25","author":"Grauer","year":"1993","journal-title":"Horm Metab Res"},{"key":"2019041123400437400_R9","first-page":"167","author":"Takahashi","year":"1995"},{"key":"2019041123400437400_R10","first-page":"S1","article-title":"Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis","volume":"8","author":"Eddy","year":"1998","journal-title":"Osteoporosis Int"},{"key":"2019041123400437400_R11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF01622285","article-title":"Calcitonin vs. etidronate for the treatment of postmenopausal osteoporosis: a meta-analysis of published clinical trials.","volume":"7","author":"Cardona","year":"1997","journal-title":"Osteoporosis Int"},{"key":"2019041123400437400_R12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/qjmed\/92.3.143","article-title":"Effect of calcitonin on vertebral and other fractures.","volume":"92","author":"Kanis","year":"1999","journal-title":"Q J Med"},{"key":"2019041123400437400_R13","author":"Stock","year":"1997"},{"key":"2019041123400437400_R14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.","volume":"109","author":"Chesnut III","year":"2000","journal-title":"Am J Med"},{"key":"2019041123400437400_R15","author":"Mulrow","year":"1997"},{"key":"2019041123400437400_R16","first-page":"49","author":"Genant","year":"1987"},{"key":"2019041123400437400_R17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/096228029300200202","article-title":"The statistical basis of meta-analysis.","volume":"2","author":"Fleiss","year":"1993","journal-title":"Stat Methods Med Res"},{"key":"2019041123400437400_R18","author":"Hedges","year":"1985"},{"key":"2019041123400437400_R19","first-page":"358","article-title":"Treatment of postmenopausal osteoporosis with salmon calcitonin nasal spray: evaluation by bone mineral content and biochemical patterns.","volume":"31","author":"Tolino","year":"1993","journal-title":"Int J Clin Pharm Ther Tox"},{"key":"2019041123400437400_R20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF00297289","article-title":"Three year calcitonin combination therapy for postmenopausal osteoporosis with crush fractures of the spine.","volume":"50","author":"Szucs","year":"1992","journal-title":"Calcif Tissue Int"},{"key":"2019041123400437400_R21","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1007\/BF01623004","article-title":"Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin","volume":"3","author":"Adami","year":"1993","journal-title":"Osteoporosis Int"},{"key":"2019041123400437400_R22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF02556055","article-title":"Effect of calcitonin and vitamin D on osteoporosis.","volume":"45","author":"Genaro","year":"1989","journal-title":"Calcif Tissue Int"},{"key":"2019041123400437400_R23","first-page":"83","article-title":"An analgesic effect of synthetic human calcitonin in patients with primary osteoporosis.","volume":"28","author":"Kapuscinski","year":"1996","journal-title":"Mater Med Pol"},{"key":"2019041123400437400_R24","first-page":"784","article-title":"Activity of salmon calcitonin in senile osteoporosis.","volume":"49","author":"Granata","year":"1991","journal-title":"Cur Ther Res"},{"key":"2019041123400437400_R25","first-page":"620","article-title":"A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.","volume":"82","author":"Hodsman","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041123400437400_R26","first-page":"242","article-title":"[Comparison of the effectiveness of 17-beta-estradiol and calcitonin in women with postmenopausal bone loss].","volume":"136","author":"Stepan","year":"1997","journal-title":"Casopis Lekaru Ceskych"},{"key":"2019041123400437400_R27","first-page":"3033","article-title":"[Calcifediol and calcitonin in the therapy of rheumatoid arthritis. A short-term controlled study.]","volume":"73","author":"Dottori","year":"1982","journal-title":"Minerva Med"},{"key":"2019041123400437400_R28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1046\/j.1365-2265.1997.d01-1750.x","article-title":"Treatment of postmenopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: a placebo controlled study.","volume":"46","author":"Gonnelli","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041123400437400_R29","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/BF00334545","article-title":"Rectal salmon calcitonin for the treatment of postmenopausal osteoporosis.","volume":"51","author":"Overgaard","year":"1992","journal-title":"Calcif Tissue Int"},{"key":"2019041123400437400_R30","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0011-393X(95)85007-4","article-title":"Effectiveness and safety of medium and long-term elcatonin use in the prevention and treatment of bone mass loss.","volume":"56","author":"Jimenez","year":"1995","journal-title":"Curr Ther Res"},{"key":"2019041123400437400_R31","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1172\/JCI113725","article-title":"Bone turnover in osteoporosis, effect of calcitonin treatment.","volume":"82","author":"Civitelli","year":"1988","journal-title":"J Clin Invest"},{"key":"2019041123400437400_R32","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0026-0495(84)90187-2","article-title":"Long-term calcitonin therapy in postmenopausal osteoporosis","volume":"Exp1","author":"Gruber","year":"1984","journal-title":"Metab Clin"},{"key":"2019041123400437400_R33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF03350260","article-title":"Intranasal and intramuscular human calcitonin in female osteoporosis in Paget\u2019s disease of bones: a pilot study.","volume":"14","author":"Pontiroli","year":"1991","journal-title":"J Endocrinol Invest"},{"key":"2019041123400437400_R34","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/BF00308314","article-title":"Long and short term side effects and safety of calcitonin in man: a prospective study.","volume":"53","author":"Wimalawansa","year":"1993","journal-title":"Calcif Tissue Int"},{"key":"2019041123400437400_R35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/8756-3282(93)90356-F","article-title":"Hip fracture in Italy: epidemiology and preventive efficacy of bone-active drugs.","volume":"14","author":"Mazzuoli","year":"1993","journal-title":"Bone"},{"key":"2019041123400437400_R36","author":"Chesnut CH","year":"1993"},{"key":"2019041123400437400_R37","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0028-2243(92)90214-J","article-title":"Effect of hormone replacement therapy and calcitonin on bone mass in postmenopausal women.","volume":"47","author":"Meschia","year":"1992","journal-title":"Eur J Obstet Reprod Biol"},{"key":"2019041123400437400_R38","first-page":"176","article-title":"Treatment of primary osteoporosis with calcium and salmon calcitonin.","volume":"115","author":"Ringe","year":"1990","journal-title":"DMW"},{"key":"2019041123400437400_R39","first-page":"57","article-title":"Lasequenza calcitriolo-calcitonina nella terapia dello\u0301steoporosi.","volume":"14","author":"Passeri","year":"1987","journal-title":"Minerva Endocr"},{"key":"2019041123400437400_R40","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2362.1994.tb01108.x","article-title":"A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium.","volume":"24","author":"Reginster","year":"1994","journal-title":"Eur J Clin Invest"},{"key":"2019041123400437400_R41","first-page":"169","article-title":"Efficacia clinica di un trattamento con calcitonia di salmone, somministrata per via endonasale per un anno nell\u2019osteoporosi postmenopausale stabilizzata.","volume":"14","author":"Agnusdei","year":"1989","journal-title":"Minerva Endocrinol"},{"key":"2019041123400437400_R42","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0169-6009(92)90883-F","article-title":"Salmon calcitonin reduces vertebral fracture in postmenopausal crush fracture syndrome.","volume":"16","author":"Rico","year":"1992","journal-title":"Bone Miner"},{"key":"2019041123400437400_R43","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2362.1994.tb01108.x","article-title":"A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium.","volume":"24","author":"Reginster","year":"1994","journal-title":"Eur J Clin Invest"},{"key":"2019041123400437400_R44","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(87)92619-5","article-title":"One year controlled randomized trial of prevention of early postmenopausal bone loss by intranasal calcitonin.","volume":"2","author":"Reginster","year":"1987","journal-title":"Lancet"},{"key":"2019041123400437400_R45","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1007\/BF02555091","article-title":"Long-term treatment of established osteoporosis with intranasal calcitonin","volume":"49","author":"Overgaard","year":"1991","journal-title":"Calcif Tissue Int"},{"key":"2019041123400437400_R46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0002-9343(90)90089-V","article-title":"Discontinuous calcitonin treatment of established osteoporosis-effects of withdrawal of treatment.","volume":"89","author":"Overgaard","year":"1990","journal-title":"Am J Med"},{"key":"2019041123400437400_R47","author":"Ribot","year":"1992"},{"key":"2019041123400437400_R48","author":"Maricic","year":"1998"},{"key":"2019041123400437400_R49","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/8756-3282(96)00084-1","article-title":"Salmon calcitonin in the prevention of bone loss at peri-menopause.","volume":"18","author":"Arnala","year":"1996","journal-title":"Bone"},{"key":"2019041123400437400_R50","first-page":"115","article-title":"Preventive treatment of cortical bone loss with salmon nasal calcitonin in early postmenopausal women.","volume":"18","author":"Mango","year":"1993","journal-title":"Minerva Endocrinol"},{"key":"2019041123400437400_R51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF02556587","article-title":"Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind study.","volume":"39","author":"Mazzuoli","year":"1986","journal-title":"Calcif Tissue Int"},{"key":"2019041123400437400_R52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF02555897","article-title":"Synthetic human calcitonin in postmenopausal osteoporosis: a placebo-controlled, double-blind study.","volume":"49","author":"Ljunhall","year":"1991","journal-title":"Calcif Tissue Int"},{"key":"2019041123400437400_R53","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF02556039","article-title":"Estimated long-term effect of calcitonin treatment in acute osteoporotic spine fractures.","volume":"45","author":"Resch","year":"1989","journal-title":"Calcif Tissue Int"},{"key":"2019041123400437400_R54","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0169-6009(89)90083-4","article-title":"Acute effect of the intranasal administration of salmon calcitonin in osteoporotic women.","volume":"7","author":"Vega","year":"1989","journal-title":"Bone Miner"},{"key":"2019041123400437400_R55","first-page":"79","article-title":"Studio comparativo randomizzato con carbocalcitonina IM vs. carbocalcitonina spray nasale vs ipriflavone x os nel trattamento dell\u2019osteoporosi post-menopausale.","volume":"17","author":"Lobianco","year":"1992","journal-title":"Minerva Endocrinol"},{"key":"2019041123400437400_R56","first-page":"1717","article-title":"Effect of eel calcitonin derivative (elcatonin) in osteoporosis.","volume":"57","author":"Yoshikawa","year":"1983","journal-title":"J Jpn Orthop Assoc"},{"key":"2019041123400437400_R57","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s002239900281","article-title":"Complementary medical treatment for Colles\u2019 fracture: a comparative, randomized, longitudinal study.","volume":"60","author":"Crespo","year":"1997","journal-title":"Calif Tissue Int"},{"key":"2019041123400437400_R58","author":"Santi","year":"1992"},{"key":"2019041123400437400_R59","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF02556587","article-title":"Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study.","volume":"38","author":"Mazzuoli","year":"1986","journal-title":"Calcif Tissue Int"},{"key":"2019041123400437400_R60","first-page":"244","article-title":"Prevention of postmenopausal bone loss with intranasal calcitonin.","volume":"51","author":"Diez","year":"1992","journal-title":"Calcif Tissue Int"},{"key":"2019041123400437400_R61","first-page":"1271","author":"Dambacher","year":"1987"},{"key":"2019041123400437400_R62","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S0140-6736(88)91712-6","article-title":"Calcitonin for the prevention of postmenopausal bone loss.","volume":"1","author":"Macintyre","year":"1988","journal-title":"Lancet"},{"key":"2019041123400437400_R63","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/BF01623839","article-title":"Effect of estrogen and calcitonin on vertebral bone density and vertebral height in osteoporotic women.","volume":"2","author":"Villareal","year":"1992","journal-title":"Osteoporosis Int"},{"key":"2019041123400437400_R64","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF01623456","article-title":"Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis.","volume":"7","author":"Flicker","year":"1997","journal-title":"Osteoporosis Int"},{"key":"2019041123400437400_R65","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0378-5122(97)00071-6","article-title":"Effects of nasal administration of calcitonin in oophorectomized women: 2-year controlled double-blind study.","volume":"28","author":"Grigoriou","year":"1997","journal-title":"Maturitas"},{"key":"2019041123400437400_R66","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s002239900291","article-title":"Comparison of calcitriol treatment with etidronate-calcitriol and calcitonin-calcitriol combinations in Turkish women with postmenopausal osteoporosis: a prospective study.","volume":"61","author":"Gurlek","year":"1997","journal-title":"Calif Tissue Int"},{"key":"2019041123400437400_R67","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/17453674.1997.11744760","article-title":"A double blind study of intranasal calcitonin for established postmenopausal osteoporosis.","volume":"275","author":"Kapetanos","year":"1997","journal-title":"Acta Orthop Scand Suppl"},{"key":"2019041123400437400_R68","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s002239900076","article-title":"Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis.","volume":"59","author":"Ellerington","year":"1996","journal-title":"Calcif Tissue Int"},{"key":"2019041123400437400_R69","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1742-1241.1998.tb08908.x","article-title":"The effect of different doses of calcitonin on bone mineral density and fracture risk in postmenopausal osteoporosis.","volume":"52","author":"Hizmetli","year":"1996","journal-title":"Int J Clin Pract"},{"key":"2019041123400437400_R70","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0378-5122(95)01022-X","article-title":"Salmon calcitonin plus intravaginal estriol: an effective treatment for the menopause.","volume":"24","author":"Melis","year":"1996","journal-title":"Maturitas"},{"key":"2019041123400437400_R71","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0378-5122(96)00999-1","article-title":"Prophylaxis of osteoporosis with calcium, estrogens and\/or eelcatonin: comparative longitudinal study of bone mass.","volume":"23","author":"Perez-Jaraiz","year":"1996","journal-title":"Maturitas"},{"key":"2019041123400437400_R72","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/8756-3282(95)00447-5","article-title":"Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis.","volume":"18","author":"Thamsborg","year":"1996","journal-title":"Bone"},{"key":"2019041123400437400_R73","first-page":"12","article-title":"[Multicenter comparative study of synthetic salmon calcitonin administered nasally in the treatment of established postmenopausal osteoporosis].","volume":"12","author":"Abellan Perez","year":"1995","journal-title":"An Med Interna"},{"key":"2019041123400437400_R74","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0002-9343(99)80344-1","article-title":"A double-blind placebo-controlled, dose finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine loss.","volume":"98","author":"Reginster","year":"1995","journal-title":"Am J Med"},{"key":"2019041123400437400_R75","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/BF00298586","article-title":"Prevention of postmenopausal bone loss by rectal calcitonin.","volume":"56","author":"Reginster","year":"1995","journal-title":"Calcif Tissue Int"},{"key":"2019041123400437400_R76","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00298606","article-title":"Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study.","volume":"56","author":"Rico","year":"1995","journal-title":"Calcif Tissue Int"},{"key":"2019041123400437400_R77","author":"Campodarve","year":"1994"},{"key":"2019041123400437400_R78","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/BF00316282","article-title":"Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis.","volume":"54","author":"Kollerup","year":"1994","journal-title":"Calcif Tissue Int"},{"key":"2019041123400437400_R79","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/BF00297179","article-title":"Effect of intranasal calcitonin therapy on bone and bone turnover in early postmenopausal women; a dose response study.","volume":"55","author":"Overgaard","year":"1994","journal-title":"Calcif Tissue Int"},{"key":"2019041123400437400_R80","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/jbmr.5650090110","article-title":"Long term (3 years) prevention of trabecular bone loss with low-dose intermittent nasal salmon calcitonin.","volume":"9","author":"Reginster","year":"1994","journal-title":"J Bone Miner Res"},{"key":"2019041123400437400_R81","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF01352009","article-title":"A clinical trial of the effects of a combination of elcatonin and conjugated estrogens on vertebral bone mass in early postmenopausal women.","volume":"53","author":"Meschia","year":"1993","journal-title":"Calcif Tissue Int"},{"key":"2019041123400437400_R82","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0378-5122(92)90206-J","article-title":"Effects of continuous and cyclic nasal calcitonin administration in ovariectomized women.","volume":"15","author":"Fioretti","year":"1992","journal-title":"Maturitas"},{"key":"2019041123400437400_R83","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/BF00301638","article-title":"An effective regimen of intranasal salmon calcitonin given in early postmenopausal bone loss.","volume":"50","author":"Gennari","year":"1992","journal-title":"Calcif Tissue Int"},{"key":"2019041123400437400_R84","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1136\/bmj.305.6853.556","article-title":"Effect of salcalcitonin given intranasally on bone mass and fracture rated in established osteoporosis: a dose-response study.","volume":"305","author":"Overgaard","year":"1992","journal-title":"BMJ"},{"key":"2019041123400437400_R85","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000294874","article-title":"Intranasal salmon calcitonin in postmenopausal osteoporosis: effect of different therapeutic regimens on vertebral and peripheral bone density.","volume":"33","author":"Perrone","year":"1992","journal-title":"Gynecol Obstet Invest"},{"key":"2019041123400437400_R86","author":"Stevenson","year":"1992"},{"key":"2019041123400437400_R87","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/BF02556148","article-title":"Effect of different doses of nasal calcitonin on bone mass.","volume":"48","author":"Thamsborg","year":"1991","journal-title":"Calcif Tissue Int"},{"key":"2019041123400437400_R88","author":"Meunier"},{"key":"2019041123400437400_R89","author":"Tremollieres"},{"key":"2019041123400437400_R90","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/bmj.299.6697.477","article-title":"Effect of salcatonin given intranasally on early postmenopausal bone loss.","volume":"299","author":"Overgaard","year":"1989","journal-title":"Br Med J"},{"key":"2019041123400437400_R91","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2265.1989.tb00443.x","article-title":"Nasal calcitonin for treatment of established osteoporosis.","volume":"30","author":"Overgaard","year":"1989","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041123400437400_R92","first-page":"455","article-title":"Comparative effects on bone mineral content of calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis.","volume":"38","author":"Gennari","year":"1985","journal-title":"Curr Ther Res"}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/edrv\/article-pdf\/23\/4\/540\/8861060\/edrv0540.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T09:56:30Z","timestamp":1682330190000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/23\/4\/540\/2433276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,8,1]]},"references-count":92,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,11,7]]},"published-print":{"date-parts":[[2002,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/er.2001-6002","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,8,1]]}}}